Angioimmunoblastic T-cell lymphoma (AITL) is a rare hematologic neoplasm that typically presents with B symptoms, anemia, and lymphadenopathy. Its overall prognosis is poor, with a 5-year survival rate of 30%. We present a case of AITL that went into spontaneous remission, an uncommon occurrence.
. Results of a peripheral smear, blood cultures, and urinalysis were all negative, and the chest x-ray showed no infi ltrates. Computed tomography scan of the abdomen revealed periaortic and periportal lymphadenopathy and splenomegaly. Flow cytometry revealed no increase in aberrant CD3/CD16-positive T cells or increase in natural killer cells. T-cell receptor gene rearrangement showed clonal T cells. Due to the clinical presentation and elevated infl ammatory markers (Table 2) , he was diagnosed with acute prostatitis. Ciprofl oxacin led to prompt resolution of fevers. He was discharged home on day 5 with antibiotics but returned within a week due to fever recurrence. At this time, magnetic resonance imaging of the prostate Spontaneous complete remission of angioimmunoblastic T-cell lymphoma Michael S. Humeniuk, MD, Jackson J. Liang, DO, Matthew Howard, MD, and David J. Inwards, MD ruled out prostatic abscess. Echocardiogram showed no sign of endocarditis, but revealed bicuspid aortic valve stenosis. He was continued on antibiotics for presumed persistent prostatitis. Two weeks after this second discharge he was hospitalized again due to recurrent fevers and urinary symptoms. He now had progressive anemia and splenomegaly palpable to 2 cm below the costal margin. Biopsies of a hypervascular cervical lymph node revealed an atypical lymphoid infi ltrate with clonal T-cell receptor gene rearrangements suspicious for T-cell lymphoma versus reactive paracortical T-cell hyperplasia. A positron emission tomography-computed tomography (PET-CT) scan (Figure 1a ) revealed signifi cant fl uorodeoxyglucose (FDG)-avid splenomegaly and lymphadenopathy both above and below the diaphragm, worrisome for lymphoma.
Bone marrow biopsy revealed an atypical T-cell infi ltrate suggestive of peripheral T-cell lymphoma, with no cytogenetic abnormalities. Subsequently, excisional biopsy of two FDGavid cervical lymph nodes confi rmed a diagnosis of AITL with patchy EBV uptake ( Figure 2 ). He was discharged on oral ciprofl oxacin for outpatient follow-up. Prostate-specific antigen (ng/mL) <4.5 9.4 His fevers improved and due to the clinical improvement, he sought out a second opinion on his diagnosis at a second large academic cancer center. Th is center confi rmed that the clinical picture and histopathological specimen were most consistent with AITL and recommended a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and vorinostat. Prior to initiation of chemotherapy, he underwent successful aortic valve replacement with a bioprosthesis and two-vessel coronary artery bypass grafting.
At his hematology follow-up 3 weeks after cardiac surgery, he was asymptomatic and denied recurrence of fevers, night sweats, and lymphadenopathy. Prechemotherapy PET-CT (Figure 1b) was performed, which showed no evidence of FDGavid lymphadenopathy, suggesting complete spontaneous remission. He had received no therapy (including corticosteroids) between the two PET-CT scans and thus he was not started on chemotherapy. He returned for follow-up 6 months later and a repeat PET was performed, which showed no FDG-avid lymph nodes but did show increased marrow FDG avidity with elevated LDH. A bone marrow biopsy showed atypical lymphocytes and persistently decreased hematopoiesis but no signs of lymphoma. Two weeks later without any therapy, the LDH declined to 235 U/L and continued to decline. From this point forward he had no further lymphoma recurrence. For his hypoproliferative anemia, he was started on transfusions and prednisone therapy. He responded well and after 1 month was no longer transfusion dependent. Prednisone was subsequently tapered from 80 mg daily and discontinued 3 months later. At outpatient follow-up 12 months after being off corticosteroids, his lymphoma remained in remission.
DISCUSSION
AITL is a rare hematologic disease that classically presents with lymphadenopathy, hepatosplenomegaly, hypergammaglobulinemia, anemia, and B-type symptoms and is distinguished by distinctive lymph node architecture disruption. AITL subjects typically present with the previously mentioned symptoms and have a mostly nondiagnostic workup until a full lymph node excision is performed. Th e lymph node biopsies show eff acement of the lymph node architecture. Bone marrow or other lymphoid organ biopsies can be abnormal but typically show a nonspecifi c polymorphic infl ammatory infi ltrate (1). Although the disease was thought to be possibly premalignant when fi rst discovered, there are clonal T cells present (2) , and research has been directed to identify the origin of these cells. Th e majority of cells are typically CD4 positive, but there does seem to be an overproduction of follicular helper T cells, showing CD10 positivity, PD-1 (CD279) positivity (3), and often Bcl-6 positivity (4), which are thought to be the likely precursor cells. Supporting this view is the fi nding of increased amounts of CXCL13, which is produced by follicular helper T cells for helping B cells migrate to germinal centers in and around the abnormal cells (5) . Analysis also shows the presence of EBV-positive B cells, but the signifi cance of EBV infection in the setting of AITL remains unclear. Th e presence of the EBV-positive B cells, which were present in our patient, may be a result of acquired immunodefi ciency from the malignancy or a consequence of unregulated T and B cell interaction, with the proliferation of the abnormal B cells being merely a bystander phenomenon (2) .
Th e disease has a relatively poor prognosis, with an overall survival at 5 years of 30% to 35% and a median survival of 36 months (2) . Currently used regimens include CHOP (and rituximab plus CHOP as the role of B-cell proliferation is still uncertain in the disease process) (6) and cyclophosphamide, vincristine, and prednisone. Since it is a T-cell malignancy, the use of cyclosporine has been introduced as a potential therapy (7) . In a retrospective study, 8 of 12 subjects responded to therapy, with 3 having a complete response. Another new therapy is alemtuzumab, a monoclonal antibody to CD52 expressed by most of the T cells in this disease (8) . Interestingly in this disease, most subjects die from overwhelming infection rather than direct lymphoma progression. Th is has led many to believe that this disease causes an acquired immunodefi ciency that has yet to be elucidated (2) . Our subject had most of the typical features at initial presentation, with anemia, lymphadenopathy, hepatosplenomegaly, B symptoms, and elevated LDH. Although some of the initial B symptoms could have been related to prostatitis, the subsequent anemia and fevers after antibiotics were more likely the direct result of the lymphoma and would have eventually led to his diagnosis.
Th e spontaneous remission of AITL without therapy is quite unusual and, although not unknown to the medical literature (9) (10) (11) , is still a very rare occurrence. Little is known regarding predictors of spontaneous remission; however, one study showed factors that might predict this event (11) . It showed that having an extra third chromosome was associated with a higher chance of spontaneous remission (P = 0.02) and an extra X chromosome showed an insignifi cant trend for less chance of remission (P = 0.09). Our patient did not have extra chromosomes. Careful surveillance following spontaneous remission is necessary, as many in the literature subsequently relapsed.
